HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Revlon investment

This article was originally published in The Rose Sheet

  • News

Executive Summary

MacAndrews & Forbes, the investment firm owned by Revlon majority investor Chairman Ronald Perelman, will provide company with up to $100 mil. next year to execute its growth plan initiatives, Revlon announces Nov. 14. MacAndrews & Forbes also agrees to provide firm $25 mil. to be available immediately. Investments will be unsecured loans and are "consistent with the progress the company has achieved in strengthening its brands and its relationships with retail customers," the firm states. CEO Jack Stahl announced during Revlon's third quarter sales and earnings call that the company had nearly exhausted its line of credit but remained confident it would find the resources it needs (1"The Rose Sheet" Nov. 3, 2003, p. 7)...

Table

View full table

Tags:
Latest Headlines

Unilever Adjusts Sustainable Plastic Goals As Industry Aspirations Meet Systemic Realities

First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle

‘Cowboy Companies’ To Be Named, Shamed And Fined Under EU Supply Chain Directive

Beauty Firms Should Draft AI Use Policies, Even If They Don’t Plan To Use AI – Attorney

See All
UsernamePublicRestriction

Register

RS011681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By